+1-781-366-7049 BostonGene Corporation, a biomedical software company, today announced the appointment of Nathan Fowler, M.D., to the newly created position of Chief Medical Officer (CMO). Dr. Fowler has published over 150 articles in peer-reviewed journals as well as numerous textbooks on innovative approaches to cancer therapy. Fowler to Provide Strategic Direction for BostonGene in its Mission to Cure Cancer.

Dr. Fowler has published over 150 articles in peer-reviewed journals as well as numerous textbooks on innovative approaches to cancer therapy. He also led development of one of the first combination immunotherapy regimens for untreated lymphomas, and is the primary investigator for the ongoing international phase III study with the combination. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. Connect with the definitive source for global and local news, https://www.businesswire.com/news/home/20200227005211/en/. Nathan Fowler and colleagues investigated the efficacy and safety of rituximab in combination with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in a phase II study. About BostonGene Corporation Prior to his work in medicine, Dr. Fowler served in the U.S. Army as a nuclear, biological and chemical defense specialist. Press release content from Business Wire. Dr. Fowler received his medical degree from the University of Texas, having completed his internship and residency there as well.

Bostongene serves customers in the United States. “We’re thrilled to welcome Dr. Fowler to BostonGene as a senior member of our management team,” said Andrew Feinberg, President and CEO at BostonGene. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision-making in the fight against cancer. News About Companies in Silicon Valley and the Bay Area, Fowler to Provide Strategic Direction for BostonGene in its Mission to Cure Cancer. View Nathan Fowler, MD’S profile on LinkedIn, the world's largest professional community. Fowler to Provide Strategic Direction for BostonGene in its Mission to Cure Cancer. “We’re thrilled to welcome Dr. Fowler to BostonGene as a senior member of our management team,” said Andrew Feinberg, President and CEO at BostonGene. View source version on businesswire.com:https://www.businesswire.com/news/home/20200227005211/en/, KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS, INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY OTHER HEALTH SOFTWARE BIOTECHNOLOGY, PUB: 02/27/2020 09:00 AM/DISC: 02/27/2020 09:01 AM, http://www.businesswire.com/news/home/20200227005211/en. Dr. Fowler brings more than 20 years of patient care experience to BostonGene—most recently as a Professor of Medicine in the Department of Lymphoma/Myeloma at the University of Texas, MD Anderson Cancer Center. University Office Park III Dr. Fowler received his medical degree from the University of Texas, having completed his internship and residency there as well. He also led development of one of the first combination immunotherapy regimens for untreated lymphomas, and is the primary investigator for the ongoing international phase III study with the combination. BostonGeneErin O’Reilly I look forward to working with cancer centers from around the globe to drive change and improve the outcomes of all patients battling cancer.”. WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene Corporation, a biomedical software company, today announced the appointment of Nathan Fowler, M.D., to the newly created position of Chief Medical Officer (CMO).Dr. He also led development of one of the first combination immunotherapy regimens for untreated lymphomas, and is the primary investigator for the ongoing international phase III study with the combination. OLATHE, Kan.–(BUSINESS WIRE)–Garmin International Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), today announced it has received European Aviation Safety Agency (EASA) cer…, Interactive real-time Twitch Storm event promises to build communities and reward viewers BostonGene integrates the analysis of individual tumor genetics, molecular composition, and microenvironment with the knowledgebase and databases of patients with similar diagnosis. Dr. Fowler received his medical degree from the University of Texas, having completed his internship and residency there as well.